Enzo Biochem, Inc. (NYSE:ENZ) Files An 8-K Other Events
Item 8.01
On December 5, 2019, Enzo Biochem, Inc. (the “Company”) issued a press release announcing that it had issued a letter to shareholders of the Company in connection with the Company’s upcoming Annual Meeting of Shareholders scheduled to be held on January 31, 2019. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 8.01.
(d) Exhibits.
| Press release issued by Enzo Biochem, Inc. on December 5, 2019. |
_____________________________________________________________________________________________
ENZO BIOCHEM INC Exhibit
EX-99.1 2 c94717_ex99-1.htm Exhibit 99.1 Enzo Biochem Issues Open Letter to Shareholders Short-Term Activist Harbert,…
To view the full exhibit click here
About Enzo Biochem, Inc. (NYSE:ENZ)
Enzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. It offers a menu of molecular and other clinical laboratory tests or procedures. Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Enzo Therapeutics is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. Its products in the development pipeline include a range of assays for detection of various women’s health infectious agents, as well as for use in the identification of pathogens for other markets.
